肝星状细胞
吡非尼酮
化学
细胞生物学
下调和上调
脂质代谢
信号转导
脂滴
肝纤维化
纤维化
甾醇调节元件结合蛋白
脂肪肝
细胞内
肝损伤
细胞信号
脂肪性肝炎
癌症研究
代谢途径
肝细胞学
药理学
β氧化
生物化学
内分泌学
泡沫电池
脂肪变性
生物
脂质氧化
细胞
脂肪酸合酶
内科学
作者
Yuelu Lan,Sijia Li,Zhu S,Can Pan,Kai Fu,Xueping Wang,L Y Fu,Fang Wang
摘要
Chronic liver injury is characterized by sustained activation of transforming growth factor-β (TGF-β) signaling within the fibrotic microenvironment, yet the contribution of TGF-β-associated metabolic remodeling to hepatic stellate cell (HSC) activation remains incompletely understood. Here, we investigated whether TGF-β signaling is associated with lipid metabolic remodeling in HSCs and whether pirfenidone (PFD) interferes with this process. We found that TGF-β1 was spatially associated with lipid accumulation in fibrotic liver tissue and that TGF-β1/2 promoted HSC proliferation. In vitro, TGF-β1/2 coordinately upregulated sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN), accompanied by increased intracellular lipid accumulation and enhanced oleic acid (OA)-associated lipid responses. Low-dose OA further activated AKT/ERK/p70 S6K signaling in HSCs, whereas PFD attenuated these signaling events. In parallel, PFD suppressed TGF-β-associated lipid accumulation in vitro, reduced SREBP1/FASN expression in activated HSC-rich regions in vivo, and alleviated CCl4-induced liver fibrosis. Together, these findings support a model in which TGF-β-associated lipogenic remodeling contributes to HSC activation and suggest that interference with this metabolic state may represent one component of the antifibrotic action of pirfenidone.
科研通智能强力驱动
Strongly Powered by AbleSci AI